Jillian Connell News Today

About contact with chairman adam schiff. We are talking about a climate the existential threat of Global Warming. So i will now make it official. Meatless mondays will be in effect and we are proud of that. You are the one thing in my way ugly. Steve remember back in the day back in School Mystery meat i dont know what that is. Now here in new york city for the 1. 1 Million School kids, every monday is going to be meatless. So you dont have to worry what that meat is because its not meat. Brian ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Sanofi’s exclusive worldwide license agreement for Maze’s glycogen synthase 1 (GYS1) pro...

Data Presented During ASN Kidney Week 2023 Demonstrate Significant Reversal of Albuminuria in Chronic Disease ModelFirst-in-Human Trial of MZE829 Development Candidate Anticipated to Begin by End of 2023SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new p...

Share this article Share this article INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus proprietary Biclonics ® platform along with the scientific and rational drug design expe...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with ... Merus N.V.January 7, 2021 GMT UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. F...

Merus N.V. Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-sta...